Type 1 Diabetes Mellitus (T1DM) Model in Bama Minipigs

Model Description

Type 1 Diabetes Mellitus (T1DM) ranks as the third leading cause of global chronic disease mortality, driving urgent demand for translational preclinical models. Our STZ-induced diabetic minipig model leverages the unique advantages of Bama minipigs:

1. Human-like glucose metabolism:

• Fasting glucose range: 3.9-6.1 mmol/L (normal) → ≥7.0 mmol/L (diabetic)
• OGTT response curves mirroring human physiology

2. Anatomical fidelity: Pancreatic islet architecture 89% homologous to humans

3. Multi-organ toxicity profiling: Validated肝肾 safety thresholds (ALT <80 U/L, Cr <1.5 mg/dL)

Why Minipigs?
✓ Superior scalability for long-term metabolic studies (6-24 months)
✓ Ideal for medical device testing: Continuous glucose monitoring (CGM) compatibility
✓ Ethical compliance: AAALAC-accredited protocols vs primate limitations

Applications

• Beta-cell regeneration therapy validation
• Closed-loop insulin pump evaluation
• Diabetic nephropathy/hepatopathy mechanism studies
• Islet transplantation protocol optimization

Modeling Protocol —— Single-Dose STZ Induction

Preconditioning:

• 12h fasting with ad libitum water access
• Baseline HbA1c & OGTT profiling

2. STZ Administration:

• IV injection: 150 mg/kg STZ in citrate buffer (pH 4.5)
• Blood glucose stabilization monitoring (Days 3-7)

3. Success Criteria:
✓ Classic symptoms: Polydipsia, polyuria, weight loss
✓ Fasting glucose ≥7.0 mmol/L (confirmed twice)
✓ Random glucose ≥11.1 mmol/L + HbA1c ≥6.5%

Validation & Testing

 Technical Advantages